Index

Abbreviations; PCNL, percutaneous nephrolithotomy; RCC, renal cell carcinoma; TCC, transitional cell cancer/carcinoma.

Aachen model 75
academic institutions, PCNL 28
access (in PCNL to kidney) 59–63, 87–9
antegrade see antegrade renal access
in antegrade ureteric stenting 162, 163, 165
complications related to establishment of 51
in endoscope-guided PCNL 119–20, 122
historical perspectives 3–6
in mini-PCNL 127, 128
in multi-access PCNL 136–8
outcome and 36, 38–9
in prone position 87–9
retrograde see retrograde ureteric access
sheaths see sheaths
in supine position 96, 97
tract for see tract access (in TCC) 197
Acculis Accu2i pMTA system 247
ACMI USL 2000 78, 79
active surveillance of small renal mass 205, 206–7
score card 210
acupuncture 238
adjuvant topical therapy in urothelial cancer 4, 185–6, 198
age
PCNL utilization and 28, 50
transitional cell cancer and occurrence of 176
prognosis in 178
air embolism 63
Alken metal dilators 40, 65, 68
allograft, renal, stones in 103–4
Alwall, Nils 3
American Urological Association/Society
RCC/small renal mass management 208, 211, 212, 225, 229, 237
stones and PCNL 26, 32, 46, 84, 85, 112
TCC 4
Amplatz dilators 40, 65, 66–7, 67, 68, 69
balloon dilators compared with 66–7
in prone position 91
in supine position 96
Amplatz sheath 92, 98, 121
in mini-PCNL 128, 131
analgesia
antegrade ureteric stenting 162
high-intensity focused ultrasound of RCC 254, 258, 259
analgesic abuse and transitional cell cancer 177
anatomical (congenital) renal abnormalities 35, 48–9
antegrade ureteric stenting and 167
supine position and 100–3
anesthesia in multi-access PCNL 136
AngioCath in cryotherapy of RCC 232, 233
antegrade nephrostogram see nephrostogram
antegrade renal access with stones 88, 98
combined retrograde and 117
antegrade ureteric stents 161–72
antibiotics, PCNL 33–8, 59, 61–5
antegrade ureteric stenting 162
mini-PCNL 127–8
see also urine, culture and antibiotic sensitivity
arterial bleeding in PCNL 70
AveCure system 247
bacillus Calmette–Guerin (BCG) in TCC 4, 184, 185, 186, 198
bilateral PCNL 48
tubeless 146
bilateral transitional cell cancer 176
biopsy (of histology samples), renal first image-guided 3
small masses 207–8, 216, 231, 266
before cryotherapy 244
bipolar irreversible electroporation probes 269, 273
bladder, transitional cell cancer see transitional cell cancer
bleeding (hemorrhage) in PCNL 51
dilation and 67–8, 70
in multi-access PCNL 140–1
in tubeless PCNL, minimizing 144–6
in RCC cryotherapy 234
in TCC percutaneous resection 187, 193, 198
blood loss see bleeding; hemostasis
body mass index and PCNL 33, 49–50, 146
see also obesity
Boston Scientific RF 3000 system 241
bowel (incl. colon) injury in high-intensity focused ultrasound of RCC 254
in PCNL 51–2
in supine position 99
brushite stones 47, 154
bull’s-eye sign 15, 89
bull’s-eye technique 38, 88–9, 109, 111, 112, 114
C-arm (in PCNL) 10, 60, 60–2, 87, 109, 110, 112, 114, 119, 127
in bull’s eye technique 88–9, 109
in lateral-flexed/lateral-decubitus position 109
in prone-flexed position 110, 112
in triangulation 89
calcium oxalate stones 24, 25, 47, 76, 78, 79, 80, 81, 154

© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
calculus (and bubbles/microbubbles) 48
in endoscope-guided PCNL, access to 119
infundibular stenosis 53
in mini-PCNL access to 128
perforation 141
in multi-access PCNL 137–8
perforation in PCNL 68, 70, 93, 141
in prone position, access to 88
in prone-flexed PCNL, access 110–11
problems relating to 114
in supine position 97, 99
Canadian StoneBreaker trial 40
carcinoma see renal cell carcinoma; transitional cell cancer
candidate beam set (for RCC radiosurgery) 277
carcinoma see renal cell carcinoma; transitional cell cancer
cardiovascular changes in prone or prone-flexed PCNL 107
catheters
in multi-access PCNL 135
ureteric/upper urinary 96, 97, 135, 164
double-J see double-J catheter
see also AngioCath
cavitation (and bubbles/microbubbles) 48
electrohydraulic lithotripter 80
histotripsy 281–2
in minimally invasive surgery 283, 285, 286
in supine position 97–99
Cavitron 140 system 247
chemolysis of stones 5
chemotherapy in urothelial cancer, topical adjuvant 4, 185–6, 198
chest x-ray, post-PCNL 157–8
children (pediatric patients), stones and outcome 34–5
tubeless PCNL 146
chyluria in PCNL 52
Clinical Research Office of the Endourological Society (CROES) PCNL Global Study 31, 32, 34, 35, 36, 37, 38, 40, 134
cystoscopy; ureteroscopy 71–2
computed tomography urogram in upper tract TCC 12–13
congenital renal abnormalities see anatomical renal abnormalities
consent, informed PCNL 51–4, 59, 64
mini-PCNL 126–7
multi-access PCNL 135
prolonged implantation 96
supine position and 96
ureteric/upper urinary 96–7
in endoscopic-assisted PCNL 116
in prone position 118
in supine position 98–9
in tubeless PCNL 146
complications 219–20, 234
cost-effectiveness of percutaneous RCC ablation 221
Covidien Cooltip RFA system 240–1, 244
cost (economic) PCNL utilization 29
intraoperative trouble-shooting 131
postoperative follow-up 234–5
cutaneous... see skin
in tubeless PCNL in avoidance of bleeding 145
death (mortality) PCNL and 54
dead space 254
deep vein thrombosis risk in PCNL 53–4
deterministic effects of radiation 7
diabetes and patient selection for PCNL 50
dilation of upper tract 37, 40, 64–71, 89–91
in endoscopy-guided access 120–1
failure 69–70
injection 65–7, 89–91, 96–7, 135
in mini-PCNL 128
intra-operative trouble-shooting 131
in multi-access PCNL 135, 138
outcomes 67–9
in prone position 89–91
in supine position 96–7, 98–9
diode laser for renal tissue/mass 254, 256
Diverticula, calyceal, stones in 48
double-J catheter or stent see double-J catheter
doctor in PCNL see healthcare providers; urologist
double-J (DJ; JJ) catheter or stent
antegrade ureteric stenting 164, 165, 168, 169
tubeless PCNL 147, 148
diagnosis (nephrostomy/post-PCNL) 92
outcome and 37, 41
Dripps—American Surgical Association classification system 191
diagnosis (nephrostomy/post-PCNL) 92
in endoscopic-assisted PCNL 119
in mini-PCNL 130, 132
in tubeless PCNL 147, 148
in supine position 96–7, 98–9
diabetic patient selection for PCNL 50
in prone position 118
role in urological practice 121–2
in supine position 98–9
technique 118–21
see also cystoscopy; ureteroscopy
for RCC percutaneous ablation

cybertherapy 232

high-intensity focused ultrasound 255–6

irreversible electroporation 272–3

radiofrequency ablation 240–1

radiosurgery 278

interstitial laser treatment of RCC 262–7

interventional imaging see imaging

intestinal injury see bowel

intraoperative imaging 152, 243–4, 245

nephrostomy tract establishment 9–10

RCC 15, 206

in high-intensity focused ultrasound 256–7, 258–9

in irreversible electroporation 273

in laser thermoablation 266

radiation safety and 13–14

in radiofrequency ablation 243–4

TCC (upper tract), and radiation safety 12–13

intraoperative troubleshooting (pitfalls and dangers)

PCNL 62, 69–71, 92–3

antegrade ureteric stenting 169

dilation 69–71

lithotripters 81

mini-PCNL 131–2

multi-access PCNL 140–1

in prone position 92–3

in prone-flexed/lateral-flexed position 114–15

tuberculous PCNL 148

RCC percutaneous ablation

high-intensity focused ultrasound 258–9

radiosurgery 278–9

Iris Variable Aperture Collimator 278

irreversible electroporation 265–75

ischemic damage in nephron-sparing treatment 237

J stent

double see double-J (DJ; JJ) catheter or stent single, in antegrade ureteric stenting 168

JC-200 high-intensity focused ultrasound device 257, 258

kidney

access see access

allograft, stones in 103–4

anatomical abnormalities see anatomical renal abnormalities

carcinoma see renal cell carcinoma

chronic disease

following percutaneous renal mass ablation 220

indicating percutaneous renal mass ablation 225

function

percutaneous nephrolithotomy effects 54, 68–9

percutaneous renal mass ablation effects 220

lower pole stones 47

respiratory incursion of, and high-intensity focused ultrasound 259

small masses 205–9, 215–23

dilemma 229–30

epidemiology and biology 205–9

evidence-based outcome of percutaneous management 215–23

functional impact of treatment 209–10

patient selection see patient selection

sampling/biopsy 207–8, 216

solitary

PCNL and 35, 167

RCC treatment and 225

see also entries under nephron-sparing treatment

kidney–ureter–bladder (KUB) radiographs

KUB see plain radiographs

KY2000 MW ablation system 247

L-shaped kidneys and supine

PCNL 100–3

laparoscopic approaches with RCC cryotherapy 229, 230, 234

irreversible electroporation 272, 273

laser therapy 263

microwave ablation 249

radiofrequency ablation 243

laser treatment, percutaneous RCC 262–7

stones see holmium:YAG laser

tCC 197, 266

lateral (incl. lateral flexed/lateral decubitus) positioning

for PCNL 65, 106–15, 232

instrumentation 109

intraoperative trouble-shooting 114

step-by-step technique 112

in RCC percutaneous ablation

high-intensity focused ultrasound 255

RCC percutaneous cryoablation 232

Lawson technique 117

LeVeen system 241

linear accelerator (for RCC radiosurgery) 277, 278, 279

LithoBreaker 75

Lithoclast... see Swiss Lithoclast lithotomy position for mini-PCNL 127, 128

lithotripsy

in PCNL, (lithotripters; lithotrites) 40–1, 74–83

holmium:YAG laser 80, 81, 97, 119

mini-PCNL 129–30

multi-access PCNL 135

shock wave see shock wave lithotripsy

liver

injury in PCNL 52

metastases from TCC 199–201

local recurrence see recurrence

lung see pulmonary complications; respiratory changes; respiratory infection

lymph node metastases (N in TNM staging), TCC 176

magnetic resonance imaging (MRI)

RCC (small mass)

intraoperative 14–15, 245, 257, 266

postoperative 15–16

preoperative 13

stones, preoperative 9

magnetic resonance urogram in upper tract TCC 12–13

malignant tumors

percutaneous procedures with see renal cell carcinoma; transitional cell cancer

ureteric orifice obstructed by 167

malleable sequential dilators 65

Mannheim technique in mini-PCNL 128

medical imaging radiation exposure 8

metachronous TCC 177

metal (telescopic) dilators 40, 65

supine position 96

metastases in RCC histotripsy, risk 286–7

metastases in TCC distant

liver 199–201

in TNM staging 176

endoscopic treatment of 191

lymph node (N in TNM staging) 176

microbubbles see cavitation

MicrothermX 247

microwave ablation (MWA) 237, 246–9

mini-PCNL 39, 87, 126–33

informed consent 126–7

instrumentation 127

intraoperative troubleshooting 131–2

patient positioning 127

preoperative preparation 127

step-by-step technique 128–31

mitomycin C in urothelial cancer 4, 185, 186, 198

monopolar irreversible electroporation probes 269, 272–3

mortality see death

multi-access PCNL 114–15, 134–42

mini-PCNL 130

outcome and 36, 39

smaller 39–40

multiple tumors and RCC treatment 225

musculoskeletal injuries in PCNL 54

see also skeletal anomalies

Nanoknife IRE generator 272

Nd:YAG laser see neodymium:YAG laser

needles see acupuncture; eye of the needle; incision; puncture

neodymium:YAG laser

renal mass 262, 264

experimental 263

TCC 197, 266
for RCC percutaneous ablation 230–1
cryoablation 248
high-intensity focused ultrasound 254–5
radiosurgery 276–7
see also patient positioning
private practice, PCNL 28
prone-flexed position 106–15
advantages 106–7
disadvantages 107–8
instrumentation 109
intraoperative trouble-shooting 114
multi-access PCNL 136
step-by-step technique 109–11
prostate position 84–94
PCNL 65, 84–94, 107, 118, 124, 136, 147
advantages and disadvantages 107–8
mini-PCNL 127, 128
multi-access PCNL 136
outcome and 36, 38, 39
tubeless PCNL 147
RCC percutaneous cryoablation 232
pulmonary complications in PCNL 122–3
traumatic 51–2
see also respiratory changes; respiratory incision
pulmonary embolism 53–4
pulsed high-intensity focused ultrasound 286
puncture (and puncture needles) 96
mini-PCNL 127, 128, 131
see also acupuncture; eye of the needle; incision
pyelogram, retrograde (RPG), in prone-flexed or lateral flexed approach to PCNL 109, 110, 112, 114
pyeloplasty, ureteric stent insertion during 168–9
pyrotherapy 281
radially expanding single-step nephrostomy dilator 67
radiation (in imaging of percutaneous interventions) 7–20
exposures 8
recommendations 8
stones surgery 10–12
physics 7–9
safety 9–16
sources 8
radiofrequency ablation (RFA) of renal masses 237, 238–46
complications 219–20
fundamental concepts 240
imaging after 16
imaging during 13, 14, 15
indications and contraindications 243
instrumentation 240–1
local recurrence following 216–17
long-term survival following 218, 218–19
mechanism 238
technical considerations 241–3
technique 243–6
radiographs, plain see plain radiographs
radiologist in PCNL as outcome factor 38–9
see also imaging
radiosurgery of RCC 276–81
recurrence (local)
RCC 216–17
follow-up for see follow-up
TCC 183, 186, 199
follow-up for 198
“red-out” 131
renal cell carcinoma (RCC) 203–89
consent see consent
epidemiology and biology 205–14
percutaneous ablation 215–81
alternative/less-available/newer methods 210–11, 221, 224
evidence-based outcome 215–23
imaging 13–16, 231, 243–4, 256–7, 258–9, 259–60, 266, 273
nonthermal methods 268–9, 269–70, 281–9
patient selection see patient selection
preoperative preparation see preoperative preparation
radiation safety in imaging 13–16
thermal methods see thermal ablation
renal organ see kidney
renal pelvis perforation in PCNL 66, 68, 70, 93
see also pyelogram; pyeloplasty
rendezvous stenting 165, 167, 170, 171
research, and RCC percutaneous management and consent to 227
respiratory changes and complications in PCNL 122
in prone or prone-flexed position 107
respiratory incursion of kidney and high-intensity focused ultrasound 259
retrieval of stones see stones
retrograde pyelogram (RPG) in prone-flexed or lateral flexed approach to PCNL 109, 110, 112, 114
retrograde ureteric access with stones 87–8, 97, 116–25
combined antegrade and 117
evolution 116–18
previous interventions restricting 49
ureteroscopy in see ureteroscopy
retrograde ureteroscopic approach to TCC 191, 192, 199
percutaneous approach compared with 196–7
rib cage in high-intensity focused ultrasound of RCC 258–9
see also subcostal approach; supracostal approach
rigid endoscopes 66, 71, 87, 121
multi-access PCNL 138, 141
tubeless PCNL 147
RITA (radiofrequency interstitial tissue ablation) system 240, 241, 245
RoboCouch Patient Positioning System 278
robotic manipulator (RCC radiosurgery) 277, 278
safety, radiation 9–16
sedation
antegrade ureteric stenting 162
RCC percutaneous ablation 243
semi-supine position in high-intensity focused ultrasound of RCC 255
sepsis in PCNL 52–3
sequential (serial) tract dilation 40, 60, 65, 67, 68, 69, 96, 111
dilators 65
malleable 65
in prone positions 91
serial tract dilation see sequential tract dilation
sex see gender
sheaths (ureteral access) in PCNL 67, 69
in endoscopic-assisted technique 121
in mini-PCNL 128–9
in multi-access PCNL 138
pathway 67
of radially expanding single-step nephrostomy dilator 67
shielding during nephrostomy tract establishment 11
shock wave lithotripsy (SWL) 26, 27, 28, 126, 286, 287
metastatic rate in tumor models 286
patient factors 49, 50
previous 49
residual fragments 153
stone burden and 31–2, 46–7
stone composition and 46
stone configuration and 32
stone location and 33
skeletal anomalies affecting patient selection for PCNL 50
see also musculoskeletal injuries
skin
damage in RCC percutaneous ablation cryotherapy 234
high-intensity focused ultrasound 254, 257, 259
fistula between kidney and 53
incision see incision
smoking and TCC 178–9
socioeconomic status and PCNL utilization 28
sonography see ultrasound
splenic injury in PCNL 52
Spongostan 145
staghorn calculi 23, 24, 25, 32–3
multiple access 134
preoperative imaging 7
in renal allograft 103
staging, TCC 176
stents, antegrade ureteric 161–72
see also double-J catheter or stent; J stent
step-by-step technique
in PCNL 60, 87–92
  mini-PCNL 128–31
  multi-access PCNL 136–40
  in prone position 87–92
  in prone- or lateral-flexed
  position 109–14
  tract dilation 69
  tubeless PCNL 147–8
  in RCC percutaneous ablation
  cryotherapy 232–4
  high-intensity focused ultrasound 256–8
  radiosurgery 278
stereotactic radiosurgery of RCC 276–81
stochastic effects of radiation 7–8
stone(s)/calculi, large 9–11, 21–172
  supine positioning in PCNL 65, 95–104
  subcostal approach in PCNL 69, 89, 122
  Storz Calcuson 78, 79
  Storz 27085k 79
  StoneBreaker 40, 75
struvite stones 3, 24, 25, 32, 49, 55, 79, 154
  in RCC percutaneous ablation
  characteristics of PCNL-treated stones 25
  composition and etiology 24–5
  and outcome 33, 34
  and patient selection 47
  configuration, and outcome 32–3, 34
  density, and outcome 33
  epidemiology 23–4
  extrarenal migration 53
  imaging see imaging
  location
  and outcome 33, 34
  and patient selection 47–8
  previous interventions 49
  open surgery 35, 49
  shock wave lithotripsy 49
  residual fragments 152–7
  clinical insignificant (CIRF) 42
  detection 154–7
  importance 152–3
  retrieval/extraction 91–2
  complications relating to 52–3, 114–15
  equipment 97, 133
  in multi-access PCNL 135, 138
  treatment
  chemolysis 5
  choices 31–3, 34
  outcomes 31–45
  PCNL see nephrolithotomy
  previous see subheading above
  surgical (in general) see surgery
StoneBreaker 40, 75
Storz 27085k 79
Storz Calcuson 78, 79
struvite stones 3, 24, 25, 32, 49, 55, 79, 154
subcostal approach in PCNL 69, 89, 122
supine positioning in PCNL 65, 95–104
antegrade ureteric stenting 162
  complete 98
  indications 95
  modified 97
  outcome and 36, 38, 104
  in special situations 100–4
  tubeless PCNL 147
  see also semi-supine position
  supracostal approach in PCNL 113, 123
  complications/morbidity associated
  with 122, 123, 146, 157, 194
  in prone- or lateral-flexed position 113, 136
  tubeless 146, 148
surgery
  for small renal masses
  high-risk patients 225
  nephron-sparing see nephron-sparing
treatment
  previous 225
  refusal 225
  for stones
  complications 51–3
  open, previous 35, 49
  risk evaluation 59
  see also entries under intraoperative;
  postoperative; preoperative
Surgiflo 145
survival, long-term, following percutaneous
RCC treatment 217–19
Swiss LithoBreaker 75
Swiss Lithoclast (LC) 40, 40–1, 75
Swiss Lithoclast Master/Select 40–1, 77–8
CyberWand compared with 79–80
Swiss Lithoclast Ultra 40
Synchrony Respiratory
Tracking System 278
Taiwan, TCC 175
  and Taiwan blackfoot disease 177
  teaching hospitals, PCNL 28
  evidence-based outcomes 182–8
  complications and risks 186–7, 193–4,
  198–9
  evidence-based outcomes 182–8
  historical perspectives 4
  indications 184–5, 192, 196–7
  results 199–201
  techniques 196–9, 266
  transplanted kidney, stones in 103–4
  triangulation technique 38, 60, 61–2, 109, 112, 113
tube(s), nephrostomy (NT)
in PCNL 92
  antegrade ureteric stenting and 161–5,
  167, 169
  decision-making on whether to leave or
  remove 147, 149, 156, 157
  drainage see drainage
multi-access PCNL  135, 139–40, 140, 141
tubeless PCNL and, comparisons/differences etc.  92, 143, 144, 145, 146, 147
in TCC percutaneous resection  186, 197, 198
tubeless PCNL  41, 92, 143–51
bilateral  146
definition  143–4
mini-PCNL  132
postoperative trouble-shooting and auxiliary procedures  148
tract closure and  41–2
see also totally tubeless PCNL
tuberculosis, ureteric  169
ultrasonic lithotrites/lithotripters  40, 75–6
dual ballistic and  76–80, 97
ultrasonic treatment of RCC
nonthermal  281–9
thermal see high-intensity focused ultrasound
ultrasound imaging (sonography)
 intraoperative, RCC  14–15
 in high-intensity focused ultrasound treatment  256–7, 257, 258–9
 intraoperative, stones  9, 98, 128
 intraoperative, TCC (upper tract), endoluminal  12
 postoperative, stones  153
 preoperative, RCC (small mass)  13
United States, TCC  175
ureter
 access  119
retrograde via see retrograde ureteric access
sheaths see sheaths
catheter see catheter
injury
antegrade ureteric stenting in  167
avulsion in PCNL  53
obstruction (incl. strictures and stenosis)  53, 161–72
antegrade stents in  161–72
percutaneous endopyelotomy  4–5
tuberculosis  169
ureteropelvic junction see pelvi-ureteric junction
ureteroscopy (with stones)  26, 99
anatomical abnormalities and  48, 49
economic cost  29
retrograde  48, 114, 117, 119–22
in holmium:YAG laser lithotripsy  81, 119
stone burden and  31–2, 46, 47
stone configuration and  32–3
stone location and  33, 47
ureteroscopy (with TCC)
percutaneous treatment vs.  191–2
risks  192–3
uric acid stones  24, 24–5, 179
urine
culture and antibiotic sensitivity in PCNL  38, 85, 91
mini-PCNL  127
multi-access PCNL  134, 141
diversion, stones and  49
leakage (prolonged)
after cryotherapy of RCC  234
after PCNL  157
urogram see computed tomography urogram; magnetic resonance urogram
urologist (physician) in PCNL
access obtained by  36, 38–9, 52
outcome related to  36, 38–9, 52
utilization related to  27–8
see also healthcare providers
urothelial carcinoma see transitional cell cancer
US (United States), TCC  175
venous bleeding in PCNL  70
venous thrombosis risk in PCNL, deep  53–4
viscera (organ) and tissue damage and injury
in PCNL  51–2
in supine position  99–100
in RCC percutaneous ablation
cryotherapy  234
high-intensity focused ultrasound  254, 257, 259
radiosurgery  276
in TCC percutaneous resection  193–4
visual loss in prone/prone-flexed position, postoperative  108
von Hippel–Lindau (VHL) syndrome  225
"White-out"  131
wires see guidewires and glidewires
Wolf 2137.50 electrohydraulic lithotripter  80
Wolf 2271.004 ultrasonic lithotripter  79
x-rays, plain see plain radiographs
Xchange Robotic Collimator Changer  278